高压氧治疗高原慢性失眠：一项前瞻性、随机、开放标签、平行组试验。

IF 6.3 3区医学 Q1 INFECTIOUS DISEASES

Travel Medicine and Infectious Disease Pub Date : 2025-03-13 DOI:10.1016/j.tmaid.2025.102834

Bin Sun , Jinli He , Haibo Chen , Wenming Zeng , Tingting Tian , Mirebankez Abay , Shizhu Bian , Junyong Zhao , Xia Jin , Xiaofang Tan , Chaoan Zhu , Dan Li , Wenqi Zhou , Yuanlong Zhang , Jun Shang , Jiwei Duan , Zhiming Zhao , Tao Wang , Fan Yang , Chuan Liu , Zhexue Qin

{"title":"高压氧治疗高原慢性失眠：一项前瞻性、随机、开放标签、平行组试验。","authors":"Bin Sun , Jinli He , Haibo Chen , Wenming Zeng , Tingting Tian , Mirebankez Abay , Shizhu Bian , Junyong Zhao , Xia Jin , Xiaofang Tan , Chaoan Zhu , Dan Li , Wenqi Zhou , Yuanlong Zhang , Jun Shang , Jiwei Duan , Zhiming Zhao , Tao Wang , Fan Yang , Chuan Liu , Zhexue Qin","doi":"10.1016/j.tmaid.2025.102834","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Hyperbaric oxygen (HBO) has been proposed to be effective for treating chronic insomnia at high altitudes.</div></div><div><h3>Methods</h3><div>Patients suffering from chronic insomnia at high altitude were randomly assigned at a 1:1 ratio to either the hyperbaric oxygen (HBO) treatment group or the control group for a 10-day procedure. The primary outcome was insomnia status, which was assessed via the Pittsburgh Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI). The secondary outcomes included stratified comparisons of changes in the PSQI score and ISI score, Fatigue Severity Scale (FSS) score and Hospital Anxiety and Depression Scale (HADS) score. Analyses were performed for multiple comparisons for the primary outcomes at 2-sided 0.05 significance levels with Bonferroni corrections.</div></div><div><h3>Results</h3><div>A total of 80 patients were randomized in this study, and the median age was 25.0 years (IQR, 21.25–29.75). For the primary outcome of sleep quality, the PSQI score after treatment was significantly lower in the HBO group than in the control group (4.6 ± 3.15 vs. 9.1 ± 4.02; adjusted mean difference [aMD] −3.96 [-5.26 to −2.66], <em>p</em> < 0.0001). The ISI was also significantly lower in the HBO group than in the control group (5.0 ± 4.09 vs. 9.8 ± 6.47; aMD −4.10 [95 % CI, −5.68 to −2.51], <em>p</em> < 0.0001). For the secondary outcomes, the HBO group showed improvements in terms of fatigue, anxiety, and depression. No serious adverse events were reported in either group.</div></div><div><h3>Conclusion</h3><div>HBO is an efficacious and safe treatment for chronic insomnia at high altitude.</div></div><div><h3>Trial registration</h3><div>ChiCTR2100046917.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"65 ","pages":"Article 102834"},"PeriodicalIF":6.3000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hyperbaric oxygen treatment for chronic insomnia at high altitude: A prospective, randomized, open-label, parallel-group trial\",\"authors\":\"Bin Sun , Jinli He , Haibo Chen , Wenming Zeng , Tingting Tian , Mirebankez Abay , Shizhu Bian , Junyong Zhao , Xia Jin , Xiaofang Tan , Chaoan Zhu , Dan Li , Wenqi Zhou , Yuanlong Zhang , Jun Shang , Jiwei Duan , Zhiming Zhao , Tao Wang , Fan Yang , Chuan Liu , Zhexue Qin\",\"doi\":\"10.1016/j.tmaid.2025.102834\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Hyperbaric oxygen (HBO) has been proposed to be effective for treating chronic insomnia at high altitudes.</div></div><div><h3>Methods</h3><div>Patients suffering from chronic insomnia at high altitude were randomly assigned at a 1:1 ratio to either the hyperbaric oxygen (HBO) treatment group or the control group for a 10-day procedure. The primary outcome was insomnia status, which was assessed via the Pittsburgh Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI). The secondary outcomes included stratified comparisons of changes in the PSQI score and ISI score, Fatigue Severity Scale (FSS) score and Hospital Anxiety and Depression Scale (HADS) score. Analyses were performed for multiple comparisons for the primary outcomes at 2-sided 0.05 significance levels with Bonferroni corrections.</div></div><div><h3>Results</h3><div>A total of 80 patients were randomized in this study, and the median age was 25.0 years (IQR, 21.25–29.75). For the primary outcome of sleep quality, the PSQI score after treatment was significantly lower in the HBO group than in the control group (4.6 ± 3.15 vs. 9.1 ± 4.02; adjusted mean difference [aMD] −3.96 [-5.26 to −2.66], <em>p</em> < 0.0001). The ISI was also significantly lower in the HBO group than in the control group (5.0 ± 4.09 vs. 9.8 ± 6.47; aMD −4.10 [95 % CI, −5.68 to −2.51], <em>p</em> < 0.0001). For the secondary outcomes, the HBO group showed improvements in terms of fatigue, anxiety, and depression. No serious adverse events were reported in either group.</div></div><div><h3>Conclusion</h3><div>HBO is an efficacious and safe treatment for chronic insomnia at high altitude.</div></div><div><h3>Trial registration</h3><div>ChiCTR2100046917.</div></div>\",\"PeriodicalId\":23312,\"journal\":{\"name\":\"Travel Medicine and Infectious Disease\",\"volume\":\"65 \",\"pages\":\"Article 102834\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Travel Medicine and Infectious Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1477893925000407\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Travel Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1477893925000407","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景：高压氧（HBO）已被认为是治疗高海拔地区慢性失眠的有效方法。方法：将高原慢性失眠症患者按1:1的比例随机分为高压氧治疗组和对照组，为期10天。主要结果是失眠状况，通过匹兹堡睡眠质量指数（PSQI）和失眠严重指数（ISI）进行评估。次要结局包括PSQI评分和ISI评分、疲劳严重程度量表（FSS）评分和医院焦虑抑郁量表（HADS）评分变化的分层比较。在Bonferroni校正的双侧0.05显著水平上对主要结果进行多重比较分析。结果：本研究共纳入80例患者，中位年龄为25.0岁（IQR, 21.25-29.75）。在睡眠质量主要指标方面，HBO组治疗后PSQI评分显著低于对照组(4.6±3.15∶9.1±4.02；校正平均差[aMD] -3.96 [-5.26 - -2.66], p < 0.0001)。HBO组ISI也显著低于对照组(5.0±4.09 vs 9.8±6.47；aMD -4.10 [95% CI, -5.68- -2.51], p < 0.0001)。对于次要结果，HBO组在疲劳、焦虑和抑郁方面表现出改善。两组均无严重不良事件报告。结论：高压氧治疗高原慢性失眠症安全有效。试验注册：ChiCTR2100046917。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Hyperbaric oxygen treatment for chronic insomnia at high altitude: A prospective, randomized, open-label, parallel-group trial

Background

Hyperbaric oxygen (HBO) has been proposed to be effective for treating chronic insomnia at high altitudes.

Methods

Patients suffering from chronic insomnia at high altitude were randomly assigned at a 1:1 ratio to either the hyperbaric oxygen (HBO) treatment group or the control group for a 10-day procedure. The primary outcome was insomnia status, which was assessed via the Pittsburgh Sleep Quality Index (PSQI) and the Insomnia Severity Index (ISI). The secondary outcomes included stratified comparisons of changes in the PSQI score and ISI score, Fatigue Severity Scale (FSS) score and Hospital Anxiety and Depression Scale (HADS) score. Analyses were performed for multiple comparisons for the primary outcomes at 2-sided 0.05 significance levels with Bonferroni corrections.

Results

A total of 80 patients were randomized in this study, and the median age was 25.0 years (IQR, 21.25–29.75). For the primary outcome of sleep quality, the PSQI score after treatment was significantly lower in the HBO group than in the control group (4.6 ± 3.15 vs. 9.1 ± 4.02; adjusted mean difference [aMD] −3.96 [-5.26 to −2.66], p < 0.0001). The ISI was also significantly lower in the HBO group than in the control group (5.0 ± 4.09 vs. 9.8 ± 6.47; aMD −4.10 [95 % CI, −5.68 to −2.51], p < 0.0001). For the secondary outcomes, the HBO group showed improvements in terms of fatigue, anxiety, and depression. No serious adverse events were reported in either group.

Conclusion

HBO is an efficacious and safe treatment for chronic insomnia at high altitude.

Trial registration

ChiCTR2100046917.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Travel Medicine and Infectious Disease PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-INFECTIOUS DISEASES

CiteScore

19.40

自引率

1.70%

发文量

211

审稿时长

49 days

期刊介绍： Travel Medicine and Infectious Disease Publication Scope: Publishes original papers, reviews, and consensus papers Primary theme: infectious disease in the context of travel medicine Focus Areas: Epidemiology and surveillance of travel-related illness Prevention and treatment of travel-associated infections Malaria prevention and treatment Travellers' diarrhoea Infections associated with mass gatherings Migration-related infections Vaccines and vaccine-preventable disease Global policy/regulations for disease prevention and control Practical clinical issues for travel and tropical medicine practitioners Coverage: Addresses areas of controversy and debate in travel medicine Aims to inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease Publication Features: Offers a fast peer-review process Provides early online publication of accepted manuscripts Aims to publish cutting-edge papers